Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases.
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Gelatinases, belonging to the matrix metalloproteases, contribute to tissue destruction in inflammatory demyelinating disorders of the central nervous system such as multiple sclerosis. We used experimental autoimmune encephalomyelitis (EAE) as an animal model to evaluate the effect of a hydroxamate matrix metalloprotease inhibitor (GM 6001) on inflammatory demyelination. A single dose of the inhibitor, given intraperitoneally, provided sufficient levels in the cerebrospinal fluid of animals with EAE to induce at least a partial inhibition of the gelatinase activity in the cerebrospinal fluid. When administered daily either from the time of disease induction or from the onset of clinical signs, GM 6001 suppressed the development or reversed clinical EAE in a dose-dependent way, respectively. Animals returned to the same clinical course as the nontreated group after cessation of treatment. Animals treated from the onset of clinical signs had normal permeability of the blood-brain barrier, compared with the enhanced permeability in nontreated animals. These results indicate that matrix metalloprotease inhibition can reverse ongoing EAE. This effect appears to be mediated mainly through restoration of the damaged blood-brain barrier in the inflammatory phase of the disease, since, the degree of demyelination and inflammation did not differ between the treatment groups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structural biochemistry and activation of matrix metalloproteases
Kleiner, D. E., & Stetler-Stevenson, W. G. (1993) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(93)90040-w · Cited by 342
Gijbels, K., Masure, S., Carton, H., & Opdenakker, G. (1992) · Journal of Neuroimmunology · doi:10.1016/0165-5728(92)90192-n · Cited by 281
Self-citationTIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase
Rosenberg, G. A., Kornfeld, M., Estrada, E., Kelley, R. O., Liotta, L. A., & Stetler-Stevenson, W. G. (1992) · Brain Research · doi:10.1016/0006-8993(92)90681-x · Cited by 281
Grobelny, D., Poncz, L., & Galardy, R. E. (1992) · Biochemistry · doi:10.1021/bi00146a017 · Cited by 273
Self-citationYOUL, B. D., TURANO, G., MILLER, D. H., TOWELL, A. D., MACMANUS, D. G., MOORE, S. G., JONES, S. J., BARRETT, G., KENDALL, B. E., MOSELEY, I. F., et al. (1991) · Brain · doi:10.1093/brain/114.6.2437 · Cited by 259
The Role of Plasmhogen Activators in the Regulation of Connective Tissue Metalloproteinasesa
MURPHY, G., ATKINSON, S., WARD, R., GAVRILOVIC, J., & REYNOLDS, J. J. (1992) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1992.tb51590.x · Cited by 245
The pathological evolution of multiple sclerosis
McDonald, W. I., MILLER, D. H., & Barnes, D. (1992) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1992.tb00794.x · Cited by 196
Gijbels, K., Proost, P., Masure, S., Carton, H., Billiau, A., & Opdenakker, G. (1993) · Journal of Neuroscience Research · doi:10.1002/jnr.490360409 · Cited by 191
Self-citationGijbels, K., van Damme, J., Proost, P., Put, W., Carton, H., & Billiau, A. (1990) · European Journal of Immunology · doi:10.1002/eji.1830200134 · Cited by 148
Self-citationStudies on the ability of 65-kDa and 92-kDa tumor cell gelatinases to degrade type IV collagen.
Mackay, A. R., Hartzler, J. L., Pelina, M. D., & Thorgeirsson, U. P. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45827-9 · Cited by 113
Cited by
The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors
Virág, L., & Szabó, C. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.3.375 · Cited by 1,373
Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors
Whittaker, M., Floyd, C. D., Brown, P., & Gearing, A. J. H. (1999) · Chemical Reviews · doi:10.1021/cr9804543 · Cited by 982
Biochemistry and Molecular Biology of Gelatinase B or Matrix Metalloproteinase-9 (MMP-9)
Van den Steen, P. E., Dubois, B., Nelissen, I., Rudd, P. M., Dwek, R. A., & Opdenakker, G. (2002) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230290771546 · Cited by 946
Multiple Sclerosis: A Coordinated Immunological Attack against Myelin in the Central Nervous System
Steinman, M. D. (1996) · Cell · doi:10.1016/s0092-8674(00)81107-1 · Cited by 903
Matrix metalloproteinases in neuroinflammation
Rosenberg, G. A. (2002) · Glia · doi:10.1002/glia.10108 · Cited by 868
Rosenberg, G. A., Estrada, E. Y., & Dencoff, J. E. (1998) · Stroke · doi:10.1161/01.str.29.10.2189 · Cited by 861
The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease
Chabas, D., Baranzini, S. E., Mitchell, D., Bernard, C. C. A., Rittling, S. R., Denhardt, D. T., Sobel, R. A., Lock, C., Karpuj, M., Pedotti, R., et al. (2001) · Science · doi:10.1126/science.1062960 · Cited by 829
Self-citationMatrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases
Hu, J., Van den Steen, P. E., Sang, Q.-X. A., & Opdenakker, G. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2308 · Cited by 795
The blood–brain and the blood–cerebrospinal fluid barriers: function and dysfunction
Engelhardt, B., & Sorokin, L. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0177-0 · Cited by 778
Glutamate excitotoxicity in a model of multiple sclerosis
Pitt, D., Werner, P., & Raine, C. S. (2000) · Nature Medicine · doi:10.1038/71555 · Cited by 744
Mediators of vascular remodelling co-opted for sequential steps in lung metastasis
Gupta, G. P., Nguyen, D. X., Chiang, A. C., Bos, P. D., Kim, J. Y., Nadal, C., Gomis, R. R., Manova-Todorova, K., & Massagué, J. (2007) · Nature · doi:10.1038/nature05760 · Cited by 727
Matrix metalloproteinases in the brain and blood–brain barrier: Versatile breakers and makers
Rempe, R. G., Hartz, A. M., & Bauer, B. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16655551 · Cited by 721
Lochter, A., Galosy, S., Muschler, J., Freedman, N., Werb, Z., & Bissell, M. J. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.139.7.1861 · Cited by 655
Matrix metalloproteinases and diseases of the CNS
Wee Yong, V., Forsyth, P. A., Bell, R., Krekoski, C. A., & Edwards, D. R. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01169-7 · Cited by 639
Demyelination: The Role of Reactive Oxygen and Nitrogen Species
Smith, K. J., Kapoor, R., & Felts, P. A. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00212.x · Cited by 600
Matrix metalloproteinases and their multiple roles in neurodegenerative diseases
Rosenberg, G. A. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70016-x · Cited by 594
Agrawal, S., Anderson, P., Durbeej, M., van Rooijen, N., Ivars, F., Opdenakker, G., & Sorokin, L. M. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051342 · Cited by 559
de Almeida, L. G. N., Thode, H., Eslambolchi, Y., Chopra, S., Young, D., Gill, S., Devel, L., & Dufour, A. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000349 · Cited by 535
Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis
Benveniste, E. N. (1997) · Journal of Molecular Medicine · doi:10.1007/s001090050101 · Cited by 533
Noble, L. J., Donovan, F., Igarashi, T., Goussev, S., & Werb, Z. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-17-07526.2002 · Cited by 494
Werner, P., Pitt, D., & Raine, C. S. (2001) · Annals of Neurology · doi:10.1002/ana.1077 · Cited by 486
Granulocyte Macrophage Colony-Stimulating Factor
McQualter, J. L., Darwiche, R., Ewing, C., Onuki, M., Kay, T. W., Hamilton, J. A., Reid, H. H., & Bernard, C. C. A. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.7.873 · Cited by 477
Gasche, Y., Fujimura, M., Morita-Fujimura, Y., Copin, J.-C., Kawase, M., Massengale, J., & Chan, P. H. (1999) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199909000-00010 · Cited by 400
Simian, M., Hirai, Y., Navre, M., Werb, Z., Lochter, A., & Bissell, M. J. (2001) · Development · doi:10.1242/dev.128.16.3117 · Cited by 391
Bar-Or, A. (2003) · Brain · doi:10.1093/brain/awg285 · Cited by 360
Stüve, O., Dooley, N. P., Uhm, J. H., Antel, J. P., Francis, G. S., Yong, V. W., & Williams, G. (1996) · Annals of Neurology · doi:10.1002/ana.410400607 · Cited by 348
Tran, E. H., Hoekstra, K., van Rooijen, N., Dijkstra, C. D., & Owens, T. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.7.3767 · Cited by 342
Wiseman, B. S., Sternlicht, M. D., Lund, L. R., Alexander, C. M., Mott, J., Bissell, M. J., Soloway, P., Itohara, S., & Werb, Z. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200302090 · Cited by 303
Astrocytes—Friends or foes in multiple sclerosis?
Williams, A., Piaton, G., & Lubetzki, C. (2007) · Glia · doi:10.1002/glia.20546 · Cited by 302
Matrix metalloproteinases degrade myelin basic protein
Chandler, S., Coates, R., Gearing, A., Lury, J., Wells, G., & Bone, E. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12173-0 · Cited by 294
Leppert, D., Waubant, E., Bürk, M. R., Oksenberg, J. R., & Hauser, S. L. (1996) · Annals of Neurology · doi:10.1002/ana.410400606 · Cited by 291
Metalloproteases regulate T‐cell proliferation and effector function via LAG‐3
Li, N., Wang, Y., Forbes, K., Vignali, K. M., Heale, B. S., Saftig, P., Hartmann, D., Black, R. A., Rossi, J. J., Blobel, C. P., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601520 · Cited by 282
Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview
Chandler, S., Miller, K. M., Clements, J. M., Lury, J., Corkill, D., Anthony, D. C. C., Adams, S. E., & Gearing, A. J. H. (1997) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(96)00179-8 · Cited by 273
Graesser, D., Solowiej, A., Bruckner, M., Osterweil, E., Juedes, A., Davis, S., Ruddle, N. H., Engelhardt, B., & Madri, J. A. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0213595 · Cited by 273
Johnson, L. L., Dyer, R., & Hupe, D. J. (1998) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(98)80122-1 · Cited by 270
Functional overlap between two classes of matrix-degrading proteases in wound healing
Lund, L. R. (1999) · The EMBO Journal · doi:10.1093/emboj/18.17.4645 · Cited by 270
Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke
Anthony, D. C., Ferguson, B., Matyzak, M. K., Miller, K. M., Esiri, M. M., & Perry, V. H. (1997) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.1997.00066.x · Cited by 268
Cuzner, M. L., & Opdenakker, G. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(98)00241-0 · Cited by 268
Matrix Metalloproteinase-9/Gelatinase B Is Required for Process Outgrowth by Oligodendrocytes
Oh, L. Y. S., Larsen, P. H., Krekoski, C. A., Edwards, D. R., Donovan, F., Werb, Z., & Yong, V. W. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-19-08464.1999 · Cited by 267
Dubois, B., Masure, S., Hurtenbach, U., Paemen, L., Heremans, H., van den Oord, J., Sciot, R., Meinhardt, T., Hämmerling, G., Opdenakker, G., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6886 · Cited by 262
Rosenberg, G. A., Estrada, E. Y., Dencoff, J. E., & Stetler-Stevenson, W. G. (1995) · Brain Research · doi:10.1016/0006-8993(95)01089-0 · Cited by 261
Leppert, D., Leib, S. L., Grygar, C., Miller, K. M., Schaad, U. B., & Holländer, G. A. (2000) · Clinical Infectious Diseases · doi:10.1086/313922 · Cited by 259
The astrocyte in multiple sclerosis revisited
Brosnan, C. F., & Raine, C. S. (2013) · Glia · doi:10.1002/glia.22443 · Cited by 259
Matrix Metalloproteinases Contribute to Brain Damage in Experimental Pneumococcal Meningitis
Leib, S. L., Leppert, D., Clements, J., & Täuber, M. G. (2000) · Infection and Immunity · doi:10.1128/iai.68.2.615-620.2000 · Cited by 259
Leppert, D., Lindberg, R. L. P., Kappos, L., & Leib, S. L. (2001) · Brain Research Reviews · doi:10.1016/s0165-0173(01)00101-1 · Cited by 255
Extracellular matrix degradation by metalloproteinases and central nervous system diseases
Lukes, A., Mun-Bryce, S., Lukes, M., & Rosenberg, G. A. (1999) · Molecular Neurobiology · doi:10.1007/bf02821717 · Cited by 230
“Animals with EAE treated with a hydroxamate MMP inhibitor showed reduced permeability of the blood-brain barrier and had fewer clinical symptoms, but the inflammatory responses were unaffected (Gijbels et al., 1994).”
Normal newt limb regeneration requires matrix metalloproteinase function
Vinarsky, V., Atkinson, D. L., Stevenson, T. J., Keating, M. T., & Odelberg, S. J. (2005) · Developmental Biology · doi:10.1016/j.ydbio.2004.12.003 · Cited by 211
Brkic, M., Balusu, S., Libert, C., & Vandenbroucke, R. E. (2015) · Mediators of Inflammation · doi:10.1155/2015/620581 · Cited by 205
“Moreover, in another study on a transgenic mouse model of AD, it was reported that inhibition of MMPs with GM6001 reduced the oxidative stress associated with CAA [86].”
BackgroundInfluentialDiverse functional roles of lipocalin-2 in the central nervous system
Jha, M. K., Lee, S., Park, D. H., Kook, H., Park, K.-G., Lee, I.-K., & Suk, K. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.12.006 · Cited by 195
Intricate Functions of Matrix Metalloproteinases in Physiological and Pathological Conditions
Mittal, R., Patel, A. P., Debs, L. H., Nguyen, D., Patel, K., Grati, M., Mittal, J., Yan, D., Chapagain, P., & Liu, X. Z. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25430 · Cited by 179
Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions
Cossins, J. A., Clements, J. M., Ford, J., Miller, K. M., Pigott, R., Vos, W., Van Der Valk, P., & De Groot, C. J. A. (1997) · Acta Neuropathologica · doi:10.1007/s004010050754 · Cited by 176
“found in the CSF during EAE [15], and inhibition of MMPs can reverse EAE [ 16 ].”
Sean Riminton, D., Körner, H., Strickland, D. H., Lemckert, F. A., Pollard, J. D., & Sedgwick, J. D. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.9.1517 · Cited by 163
Chauhan, P., Kakkar, A. K., Singh, H., & Gautam, C. S. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1838276 · Cited by 12
Lefty peptides, derived by MMP2 cleavage, act as a new class of gelatinase A inhibitor
Naidu, D. (2008) · Frontiers in Bioscience · doi:10.2741/3221 · Cited by 4
“GM6001 is a general inhibitor of all MMPs with Ki values of less than 100 nM (14-15).”
Background(1998) · Europe PMC (PubMed Central)
Metadata
- Authors
- Gijbels, K., Galardy, R. E., & Steinman, L.
- Venue
- Journal of Clinical Investigation
- Published
- 1994-12-01
- Volume
- 94
- Issue
- 6
- Pages
- 2177-2182
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2041533977
- Cited by
- 339
- References
- 20
- FWCI
- 10.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.